MAVENIR
15.12.2022 08:01:32 CET | Business Wire | Press release
Mavenir today announces the completion of radio integration at the Joint European O-RAN and TIP PlugFest, part of the O-RAN Global PlugFest Fall 2022, at the i14yLab in Berlin, hosted by Deutsche Telekom, EANTC and Vodafone. Mavenir validated its massive MIMO (mMIMO) 32TRX Active Antenna Unit (AAU) for open integration with the Keysight Technologies O-RU conformance and certification testing solution.
Mavenir’s OpenBeam mMIMO 32TRX AAU, is a high-performance O-RAN based Radio Unit (O-RU) supporting 400Mhz instantaneous bandwidth and 200 Mhz occupied bandwidth to meet high capacity and RAN sharing use cases. At 16.8kg, utilizing just passive cooling technology, it is one of industry’s lightest AAU, with uncompromising performance delivering 240W output power and high bandwidth. The AAU utilizes Zero-Force Beamforming technology to maximize performance while minimizing interference.
BG Kumar, President of Mavenir’s Access Networks, Platforms and MDE, said, “Mavenir has further strengthened the Open RAN ecosystem by introducing a competitive, high performance 32TRX mMIMO AAU O-RU product. Through the successful integration and testing at the PlugFest in Berlin, Mavenir aims to accelerate the adoption of open, disaggregated and standards-based solutions.”
Mavenir demonstrated the 32TRX AAU at PlugFest using Keysight’s Open RAN Studio Open RAN Distributed Unit (O-DU) emulator, VXT PXI Vector Transceiver, MXA/MXG signal generators, and PathWave Test Automation framework.
The 32TRX mMIMO AAU is part of the OpenBeam portfolio featuring energy efficiency capabilities, delivering savings of over 80% power consumption during idle periods. It also reduces Total Cost of Ownership (TCO) by employing AI/ML based intelligent automation for fault management, beamforming, energy efficiency, load balancing and improved network performance when used as part of Mavenir’s Open vRAN Solution. Initial 32TRX mMIMO AAU products launched this year cover 3.3GHz to 3.8GHz, targeting Europe, the Americas, and South-East Asia.
In addition to the massive MIMO AAU showcased for integration at the PlugFest, the OpenBeam O-RU portfolio also includes mmWave AAUs and multi-band RRUs for improved network capacity. The OpenBeam O-RUs are available across all frequency bands and can be used for a wide range of use cases, including enterprise and public networks for urban or rural environments.
Mavenir’s participation at the PlugFest builds upon ongoing engagements and progresses current activity in the region. Earlier in the year, Mavenir expanded its European capabilities with the establishment of an Open RAN Centre of Excellence in Germany, strengthening Mavenir’s multinational organisation by delivering regional focus, driving the knowledge and innovation across the region.
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry's only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers and Enterprises in over 120 countries, which serve more than 50% of the world’s subscribers.
i14yLab
The i14y Lab is an open lab for interoperability testing of disaggregated telco systems, such as Open RAN. The lab is operated by a consortium of strong academic and industry partners led by Deutsche Telekom and supported with funding from the German Ministry of Digital and Transport (BMDV).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005908/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom